Dr. Jeff Gregory Joins MediQuest Therapeutics, Inc.'s Management Team

(Bothell, Washington - 13 July 2006) MediQuest Therapeutics, Inc. a privately held biotechnology company specializing in infectious and inflammatory skin diseases today announced that Jeff Gregory, MD, MBA, has joined MediQuest as its Vice President for Medical Affairs and Chief Medical Officer.

"With his appointment, Jeff brings valuable medical and commercial insight to the Company," said Dr. Frederick J. Dechow, President and CEO of MediQuest. "Jeff's clinical experience as a practicing physician and his recent involvement with venture financing groups will provide MediQuest's management team with a needed dimension and added depth, as we advance additional drug candidates into clinical development."

"MediQuest Therapeutics has an exciting, novel drug discovery and delivery technology with several commercially promising candidates and a strong leadership team. MediQuest's business goals are both realistic and achievable. I value and appreciate the direction Fred and the Board of Directors have set for MediQuest. I look forward to assisting MediQuest realize their strategic vision as its Chief Medical Officer," said Gregory.

Dr. Gregory joins MediQuest having completed his MBA at the University of Washington and his internship at venture capital firms Frazier and Integra. Prior to that, he had 7 years of clinical practice at Group Health Cooperative in Seattle, WA and private practice in Boise, ID. He received his medical training at Harvard Medical School and Johns Hopkins University School of Medicine.

MediQuest is a specialty pharmaceutical company using its proprietary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company's major efforts are focused on projects targeting Raynaud's phenomenon, nail psoriasis, and actinic keratosis.